Clinical Trial

The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
CLEAR CAR-T cell injection (ET-970) is an engineered CD70-targeting allogeneic Chimeric Antigen Receptor T-Cell (CAR-T cell). This is a multi-center, single-arm, open-label, early exploratory clinical study. The objective of this study is to evaluate the safety and preliminary efficacy of ET-970 in unresectable or metastatic clear cell renal cell carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-09.
Trial Details
NCT Number NCT07645690
Lead Sponsor Chinese PLA General Hospital
Conditions Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
Enrollment 30 participants
Start Date 2026-07-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-22